APIPharm was established in 2020 by Dr. Matevz Pompe, the SWISS BIOTEC Group and Michael Bigl, CEO of the swiss OSIRIS Global Holding AG. All partners are experts in the area of high quality pharma analytics and Syntehesis.

Dr. Matevz Pompe is head of research group at University of Ljubljana, Faculty of Chemistry and Chemical Technology, Department of Analytical Chemistry. He is specialised in the development of risk assessment systems for the evaluation of shelf-life of open chemicals and advisor to the pharmaceutical industry, developing and optimizing new analytical procedures and synthetic pathways.

The SWISS Biotech Group develops and produces finished medicinal products and food supplements with the highest bioavailability and body optimization. The developed micellization technology is trend-setting.

The OSIRIS Global Holding AG produces innovative CBD products, aromatherapy and own brands that are sold through a Europe-wide distribution and sales network.

In December 2020 APIPharm enters a three year Definitive Supply Agreement with Canadian Producer Aleafia Health.

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.